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Telomeres, guanine-rich tandem DNA repeats of the chromosomal end, provide chromosomal stability, and cellular replication
causes their loss. In somatic cells, the activity of telomerase, a reverse transcriptase that can elongate telomeric repeats, is usually
diminished after birth so that the telomere length is gradually shortened with cell divisions, and triggers cellular senescence. In
embryonic stem cells, telomerase is activated and maintains telomere length and cellular immortality; however, the level of
telomerase activity is low or absent in the majority of stem cells regardless of their proliferative capacity. Thus, even in stem cells,
except for embryonal stem cells and cancer stem cells, telomere shortening occurs during replicative ageing, possibly at a slower rate
than that in normal somatic cells. Recently, the importance of telomere maintenance in human stem cells has been highlighted by
studies on dyskeratosis congenital, which is a genetic disorder in the human telomerase component. The regulation of telomere
length and telomerase activity is a complex and dynamic process that is tightly linked to cell cycle regulation in human stem cells. Here
we review the role of telomeres and telomerase in the function and capacity of the human stem cells.
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Telomere, a complex of guanine-rich repeat sequences and
associated proteins, caps and protects every eukaryotic chromo-
some end against chromosomal fusion, recombination, and
terminal DNA degradation (Blackburn, 2001). Telomeric DNA
consists of short guanine-rich repeat sequences in all eukaryotes
with linear chromosomes, and its length in human somatic cells is
remarkably heterogeneous among individuals ranging from 5 to
20kb, according to age, organ, and the proliferative history of each
cell (Wright and Shay, 2005). During a process of DNA synthesis
and cell division, telomeres shorten as a result of the incomplete
replication of linear chromosomes, the so-called ‘end-replication
problem’. This progressive telomere shortening is one of the
molecular mechanisms underlying ageing, as critically short
telomeres trigger chromosome senescence and loss of cell viability
(Collins and Mitchell, 2002; Blasco, 2005; Wright and Shay, 2005).
To prevent degradation by exonucleases or processing as damaged
DNA, the telomere 30 single-strand overhang folds back into the
D-loop of duplex telomeric DNA to form a protective ‘T-loop’,
which is reinforced with TRF2 and other telomeric DNA-binding
proteins named Shelterin (de Lange, 2005).
Telomerase is a complex of a reverse transcriptase protein
encoded by the TERT (telomerase reverse transcriptase) gene
and a template RNA TERC (telomerase RNA component).
Telomerase can add telomeric repeats onto the chromosome ends,
and prevents the replication-dependent loss of telomere and
cellular senescence in highly proliferative cells of the germline and
in the majority of cancers (Blasco, 2005). Thus, telomerase a
ctivity and telomere maintenance are associated with the
immortality of cancer cells, germ-line cells, and embryonic stem
(ES) cells.
In most human somatic cells except for stem cells and
lymphocytes, telomerase activity is diminished after birth so that
telomere length shortens with each cell division. A critical length of
telomere repeats is required to ensure proper telomere function
and avoid the activation of DNA damage pathways that result in
replicative senescence or cell death. As stem cells have elongated
proliferative capacity, they should have a mechanism that
maintains telomere length through many cell divisions. In fact,
low levels of telomerase activity have been found in human adult
stem cells including haematopoietic and non-haematopoietic stem
cells such as neuronal, skin, intestinal crypt, mammary epithelial,
pancreas, adrenal cortex, kidney, and mesenchymal stem cells
(MSCs) (Table 1). Basically, given the difference of telomere and
telomerase activity in human and mouse cells, the telomere and
telomerase status in stem cell populations is different between
humans and mice (Harrington, 2004). The level of telomerase is
low in the majority of human stem cells, whereas it is upregulated
in cells that undergo rapid expansion, such as committed
haematopoietic progenitor cells, activated lymphocytes, or kerati-
nocytes, even within tissues with a low cell turnover such as the
brain (Haik et al, 2000; Figure 1).
Mutations in telomerase core components, TERT and TERC,
have been found in patients suffering from aplastic anaemia and
dyskeratosis congenital (DKC), as described later. Both diseases
are characterised by bone marrow failure and/or skin abnormal-
ities, resulting from defects in maintaining the haematopoietic
stem cell compartment. Moreover, cancer and ageing, two
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implicated, are increasingly recognised as stem cell diseases. For
example, some cancers may originate from the transformants
of normal stem cells or progenitor cells, so-called cancer stem
cells (CSCs), whereas ageing is induced through a progressive
functional decline in certain stem cells (McEachern et al, 2000).
TELOMERES AND TELOMERASE IN HAEMATOPOIETIC
STEM CELLS
In the haematopoietic system, telomerase-expressing cells are stem
cells with self-renewal potential and their early descendants
(Hiyama et al, 1995; Morrison et al, 1996). Age-dependent loss
of telomeric DNA has been observed in both lymphocytes and
neutrophils (Vaziri et al, 1993) as well as in other tissues (Hiyama
et al, 1996; Wright and Shay, 2005). The length of telomeres in
adult blood leucocytes was reported to be shorter than that in
germline cells from the same donor (Cooke and Smith, 1986). A
subset of stem cells isolated from adult bone marrow showed
shorter telomeres than a similar subset isolated from fetal liver or
cord blood, suggesting that a progressive decline in telomere
length with age occurs in haematopoietic stem cells (HSCs) (Vaziri
et al, 1993). It is possible that transplanted HSCs derived from
aged donors may reach their proliferative limit during the lifetime
of the recipient. In fact, several cases with graft failure after HSC
transplant have been reported to have unusual telomere shortening
(Wynn et al, 1998).
Low levels of telomerase activity are readily detectable in HSCs
and in some of their differentiated progeny including peripheral
blood lymphocytes (Hiyama et al, 1995; Morrison et al, 1996).
Nevertheless, the age-related loss of telomeric DNA in these cells
suggests that telomerase activity in HSCs is insufficient to
completely prevent telomere loss. Telomere length alterations
have also been noted in myelodysplastic syndromes (MDS) and
chronic myeloid leukaemia (CML), where telomere loss in HSCs
may be associated with cellular senescence and ineffective
haematopoiesis as well as contributing to genomic instability and
subsequent leukaemic progression (Ohyashiki et al, 2002). These
data support the idea that replicative potential of HSCs could be
Table 1 Telomere and telomerase in human stem cells
Cell type Lineage Growth Telomerase Telomere Reference
Embryonic All tissue Unlimited High Maintained
Hematopoietic Multipotent Limited Absent/low Shortened Brummendorf and Balabanov (2006)
Mesenchymal Multipotent/skeletal
tissue
Limited/unlimited Absent/low upregulated
by stimuli
Shortened/maintained (Izadpanah et al, 2006; Yanada et al,
2006; Zimmermann et al, 2003)
Skin Epidermis Limited Low Shortened (Sarin et al, 2005; Sugihara et al, 1999)
Hair follicle Hair Limited Low Shortened
Intestinal crypt Intestinal mucosa Limited Low Shortened (Hiyama et al, 1996)
Neuronal
a Several neurons Limited Low/absent Shortened (Wright et al, 2006)
Pancreatic
a Ductal epithelial Limited Absent Shortened (Moriscot et al, 2005)
Liver epithelial Bi-potential Limited (durable) Low Maintained/shortened (Dan et al, 2006)
Cancer stem cell Multipotent Unlimited High Maintained (Hertzog, 2006)
aThese stem cells may be derived from hMSCs.
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Figure 1 Telomere and telomerase dynamics in human stem cells. Germ cells have high levels of telomerase activity during rapid proliferation. Although
telomerase activity is diminished in non-proliferating sperms and ova, it is highly activated after fertilisation and maintained in ES cells and germ cells for the
next generation. In the developmental stage, telomerase activity gradually decreases and diminishes in most somatic cells after birth. In adult stem cells, the
level of telomerase activity is low or undetectable, and upregulated in committed progenitor cells which have high reproducible activity in each tissue but
insufficient to stably maintain their telomere length. Thus, normal stem cells are considered to be mortal and finally senesce by telomere shortening.
Cancer stem cells can be derived from normal stem cells, progenitor cells, or possibly somatic cells and might be immortal, having the capacity of indefinite
self-renewal and proliferation.
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length can be used as an indirect indicator of stem cell proliferative
history and potential. Bone marrow insufficiency in a telomerase-
deficient disease, DKC (Vulliamy et al, 2001), may be further
evidence of that.
Telomerase activity appears to be upregulated in response to
cytokine-induced proliferation and cell cycle activation in
primitive HSCs, and progressively downregulated in more matured
subsets (Chiu et al, 1996) except for mitogenically activated
lymphocytes (Hiyama et al, 1995) (Figure 1). Stem cells are capable
of generating a very large number of committed progenitors and
their descendants during a small number of self-renewal divisions.
As such, individual stem cell turnover at any given point would be
minimal and the upregulation of telomerase activity in stem cells
could be minimal, preventing the generation of overly long
telomeres (Collins and Mitchell, 2002). Transient activation of
telomerase activity induced during periods of rapid cellular
proliferation could reduce telomere loss in lineage-committed
progenitor cells. In more mature cells, telomerase activity is
repressed irrelevant to their proliferation. These findings suggest
that one important function of telomerase in HSCs is to reduce the
rate of telomere loss during the period of rapid cell division,
preventing premature critical shortening of telomeres and loss of
telomere function. Such a role of telomerase would be critically
important in the case of increased proliferative demand, such as
infection or blood loss (Allsopp et al, 2003).
NON-HAEMATOPOIETIC STEM CELLS
Some controversial data remain in telomerase activity and TERT
expression in non-HSC (NHSCs). The difference of the levels of
telomerase activity in NHSC components of various organs is
likely derived from the difference of their cellular turnover among
organs. In this review, as representative NHSCs, we focused on
MSCs.
Stem cells for mesenchymal tissues, which can be derived from
bone marrow, are commonly termed MSCs. Mesenchymal stem
cells could differentiate into multiple mesoderm-type cell lineages
(Prockop, 1997), such as fibroblasts, adipocytes, osteoblasts,
chondrocytes, and endothelial cells, as well as into non-meso-
derm-type lineages, such as neuronal-like cells. The phenotype of
replicative senescence in cultured MSCs depends on the species.
For instance, human MSCs (hMSCs) were reported to cease
dividing rather early (around 40–50 population doublings),
whereas murine MSCs (mMSCs), that have telomerase activity,
could be passaged for more than 100 population doublings
(Meirelles Lda and Nardi, 2003). Other investigators also reported
for hMSCs that telomere length gradually shortened at a similar
rate to non-stem cells (30–120bpPD
 1) and telomerase activity
was undetectable (Fehrer and Lepperdinger, 2005). However,
several growth factors enhance the mitotic potential of hMSC,
and we recently found that bone marrow-derived hMSCs main-
tained long telomeres without the upregulation of telomerase
activity for more than 100 population doublings under culture with
basic FGF (Yanada et al, 2006). Moreover, forced telomerase
expression in hMSCs led to an extended life span and enhanced
differentiation potential (Simonsen et al, 2002). Even using highly
sensitive assays, no telomerase activity has been detected in hMSCs
so far, and there may be a mechanism of telomere maintenance
other than telomerase, such as alternative lengthening of
telomeres, in hMSCs. Recent observation of subtelomeric DNA
hypomethylation facilitating telomere elongation in mammalian
cells suggests that such epigenetic modification of chromatin may
occur in hMSCs (Gonzalo et al, 2006). On the other hand, mMSCs
with their telomerase activity knocked-down completely failed
to differentiate into adipocytes or chondrocytes, even in early
passages (Liu et al, 2004). Also in hMSCs, overexpression of
telomerase indeed resulted in the elongation of telomeres, and
TERT-transfected cells kept proliferating when untransfected
control cells ceased growth. Furthermore, the potential of
telomerase-overexpressing cells to form bone in vivo was greatly
enhanced (Simonsen et al, 2002). Most likely, telomerase is
required for both cell replication and differentiation. The latter
implies that hMSCs may express at least the minimum level of
telomerase activity to bring about regenerative capacity and
differentiation potential.
In other NHSCs, it has been shown that hepatocytes become
senescent owing to telomere shortening in the cirrhotic stage of a
wide variety of chronic human liver diseases. Intriguingly,
mesenchymal cell-like endothelial cells and hepatic satellite cells
do not show this replicative senescence (Dan et al, 2006). The
replicative senescence in hepatocytes is probably in part the result
of continued proliferation during 20–30 years of chronic liver
diseases. Chronic inflammation, the presence of growth factors,
and DNA-damaging agents such as reactive oxygen and nitrogen
species may also play a role in this process.
DISEASES DUE TO LACK OF TELOMERASE IN STEM
CELLS: DKC AND APLASTIC ANAEMIA
The critical importance of telomerase activity in human stem cells
has been recently highlighted as the aetiology of DKC. In this
disease, a defect of the telomerase RNA template gene results in the
absence of telomerase activity and premature telomere shortening,
developing bone marrow failure, intestinal disorder, or malig-
nancy, typically under 50 years old. Positional cloning identified
the gene affected in many patients with X-linked DKC as the
human homologue of yeast CBF5, termed DKC1, encoding a
protein, dyskerin. The association of the telomerase complex with
dyskerin suggested that the DKC phenotype may be the result of
altered telomerase activity (Vulliamy et al, 2001). Then, the
discovery of a 30 deletion in the gene encoding TERC in a single
large family with autosomal dominant DKC confirmed the
importance of telomerase deficiency as the aetiology for DKC
and highlighted the importance of telomerase in maintaining
cellular lifespan and replicative potential in human organs. As
mice have much longer telomeres that cannot be seriously
shortened within their short lifetime, this situation contrasts
markedly with Terc knockout mice where completely absent
telomerase activity is tolerated without abnormality in the first few
generations. After the fourth generation, Terc knockout mice begin
to exhibit abnormalities similar to the phenotype of human DKC
(Samper et al, 2002). Wild-type mice derived from late generations
of Terc þ/  mice with short telomeres and positive telomerase
activity displayed a similar phonotype of DKC, indicating that
short telomeres themselves, rather than lack of telomerase activity,
cause stem cell failure (Hao et al, 2005). Recently, Cdkn1a deletion
improved stem cell function and lifespan of mice with telomere
dysfunction, indicating that upregulation of p21 (encoded by
Cdkn1a) in response to shortened telomeres impairs repopulation
capacity of stem cells in age-related diseases and senescence
(Choudhury et al, 2007).
Aplastic anaemia results from the failure of bone marrow to
produce sufficient quantities of all haematopoietic lineages. The
aetiology of this disease is unclear in most cases, but is generally
thought to be the result of HSC damage or loss. Telomere length in
peripheral blood granulocytes and monocytes in patients with
aplastic anaemia or related disorders was significantly shorter than
that in age-matched controls, and correlated with disease duration
(Lee et al, 2001). An inverse correlation between age-adjusted
telomere length and peripheral blood counts was also observed in
aplastic anaemia (Brummendorf et al, 2001). As in DKC-associated
aplastic anaemia, a report found mutations in the TERC gene in
patients with aplastic anaemia (Vulliamy et al, 2002). Data from
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disturbed telomere maintenance may play a role in replicative
exhaustion of the HSC pool in vivo, which might be correlated with
age-related diseases and senescence.
EMBRYONIC STEM CELLS
Embryonic stem cells, more primitive stem cells, are likely to be
potentially immortal and capable of indefinite self-renewal
together with the ability to differentiate and contribute to the
germ line. Embryonic stem cells and undifferentiated embryonal
carcinoma (EC) cells display high levels of telomerase activity and
hTERT expression, both of which are rapidly downregulated
during differentiation (Armstrong et al, 2005) and much lower or
absent in somatic cells including stem cells in self-renewal tissues
(Figure 1). The downregulation of telomerase activity in differ-
entiating EC cells was reported to be tightly correlated with histone
deacetylation and DNA methylation of the TERT gene (Lopatina
et al, 2003). Moreover, increased telomerase activity enhanced self-
renewal ability, proliferation, and differentiation efficiency in Tert-
overexpressing ES cells (Armstrong et al, 2005). High telomerase
activity or the expression of TERT can therefore be regarded as a
marker of undifferentiated ES cells.
In cloned animals originating from adult nuclei with shortened
telomeres, telomere length in somatic cells has been found to be
comparable with that in age-matched normal animals originating
from a fertilised egg with long telomeres. This finding indicates
that the enucleated oocyte has the ability to reset the telomere
length of the nucleus derived from a donor adult somatic cell by
the elongation of telomeres (Meerdo et al, 2005). Elucidation of
this ‘reset’ mechanism in oocytes will be a technical breakthrough
in developing cloned animals.
CANCER STEM CELLS
The first evidence that a rare population of stem cells maintain the
human cancer came from a study on haematopoietic malignancies
(Lapidot et al, 1994). Haematopoietic malignancies can be divided
into premalignant, chronic, and acute stages, the last being the
most advanced and malignant. It is known that the premalignant
stage, such as MDS, and the chronic stage, such as CML or chronic
lymphoid leukaemia, can progress into a more malignant and
acute stage of the disease, for example, acute lymphoid or myeloid
leukaemia (Greenberg et al, 1997). In this progression, telomere
shortening in HSCs is considered to be a risk factor that
contributes to the development of chromosomal instability and
malignant transformation. In agreement with this hypothesis,
telomere shortening in patients with DKC correlates with an
increased risk of haematological neoplasia (Mason et al, 2005).
Similar to haematopoietic malignancies, several kinds of solid
cancers, especially breast and brain cancers (Singh et al, 2003;
Al-Hajj and Clarke, 2004), are considered to be generated and/or
propagated by CSCs.
To maintain their characteristic replicative ability, CSCs should
have telomere-lengthening mechanisms; however, since the
identification and purification of CSCs are difficult in most solid
tumors, the telomere and telomerase dynamics in CSCs remain
unclear. Regardless of the derivation of CSCs, normal stem cells,
committed progenitor cells, or differentiated cells (Clarke and
Fuller, 2006), CSCs might have acquired immortality by mutational
events in telomere-lengthening mechanisms, typically the activa-
tion of telomerase (Ohyashiki et al, 2002), considering that
telomere shortening and cellular senescence are inevitable in these
original cells (Figure 1), except for some MSCs. Theoretically, the
inhibition of telomerase in CSCs to limit proliferation capacity and
induce apoptosis, the stabilisation of telomeres in premalignant
lesions to prevent the activation of telomerase and transformation
to CSCs, and the identification of specific marker proteins in CSCs
in each organ are likely to optimise screening and therapeutic
interventions as novel anticancer strategies.
CONCLUSIONS
Recent research has focused on telomeres and their role in cell
cycle regulation, cellular senescence, and genetic instability;
however, much remains to be learned, and what is clear is the
complexity of telomere and telomerase interactions in cell cycle
progression and cell signaling in both normal somatic cells and
malignant cells. Both elements have a key role in determining
proliferative capacity in all human cells. Telomere shortening
occurs in most human somatic cells and triggers DNA damage
responses that mediate cell cycle arrest or apoptosis, while HSCs
can escape this trigger by employing a telomerase-dependent
telomere lengthening mechanism in replication. This process in
normal HSCs, however, appears to have only limited potential in
extending the replicative capacity, because the telomere shortening
occurs slowly but steadily in blood cells with ageing. In contrast,
CSCs should have complete telomere-lengthening mechanisms that
provide indefinite proliferation capacity. Research on telomere-
telomerase dynamics in stem cells could lead to the development of
novel aetiology-based radical therapies in ageing-related diseases
and cancers.
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